Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2008 by Maisonneuve-Rosemont Hospital.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Bayer
Information provided by:
Maisonneuve-Rosemont Hospital
ClinicalTrials.gov Identifier:
NCT00807196
First received: December 10, 2008
Last updated: NA
Last verified: December 2008
History: No changes posted

December 10, 2008
December 10, 2008
September 2008
December 2011   (final data collection date for primary outcome measure)
Engraftment, chimerism, transplant related toxicity, acute and chronic GVHD [ Time Frame: one year ] [ Designated as safety issue: Yes ]
Same as current
No Changes Posted
Overall response rate, overall and disease free survival [ Time Frame: 360 days ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma
Phase I-II Non-Randomized Study of Yttrium 90 Ibritumomab Tiuxetan (Zevalin) With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Relapsed, Refractory, or Transformed Indolent Non Hodgkin Lymphoma

The purpose of this study is to investigate the ability to combine a radioactive medication directly targeted against lymphoma cells with the immune effects of an allogeneic blood stem cell transplant.

Despite initial high response rates of low grade Non Hodgkin lymphoma, progressive or refractory disease currently remains incurable. Being a radiosensitive tumor, we hypothesize that combining different modalities of treatment including targeted radioimmunotherapy (RIT), and a graft versus lymphoma effect related to an allogeneic non myeloablative stem cell transplant may increase response and survival rates in a safe manner in patients with persistent disease following initial treatment. In this study patients who are not eligible for a standard stem cell transplant approach because of relapsed or refractory disease and who have a related sibling donor are treated with RIT followed by an allogeneic non myeloablative blood stem cell transplant

Interventional
Phase 1
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Non-Hodgkins Lymphoma
  • Drug: Rituximab
    250mg/m2 day -21 and day -14 of preparative regimen
  • Drug: 90Y ibritumomab tiuxetan (Zevalin)
    0.4 mCi/kg IV on day -14 of preparative regimen
  • Drug: Cyclophosphamide
    300mg/m2 IV daily for 5 days day -8 to day -4 of preparative regimen
  • Drug: Fludarabine
    30mg/m2 IV daily for 5 days day -8 to day -4 of preparative regimen
  • Other: Non myeloablative allogeneic stem cell transplantation
    Blood stem cell infusion on day 0
Experimental: T
Interventions:
  • Drug: Rituximab
  • Drug: 90Y ibritumomab tiuxetan (Zevalin)
  • Drug: Cyclophosphamide
  • Drug: Fludarabine
  • Other: Non myeloablative allogeneic stem cell transplantation
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
20
December 2012
December 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

Patients must have/be

  1. Age 18 to 65 years. Patients between age 66 and 69 may be enrolled if judged to be in excellent physical condition as per treating physician and study investigator and based on institutional practice.
  2. Diagnosis of Non-Hodgkin lymphoma, follicular, marginal zone, small lymphocytic lymphoma, mantle cell lymphoma or transformed from an indolent NHL to aggressive histology disease lymphoma as defined by the World Health Organization.
  3. Disease relapsed after, refractory or failing to achieve a PR after two or more cycles of intensive salvage chemotherapy (R-ESHAP or other) or disease relapsed after autologous stem cell transplantation. Poor partial response is defined as less than 50% reduction of tumor size. Salvage chemotherapy has to be administered after either 1st, 2nd or 3rd relapse
  4. Disease expressing the CD 20 antigen
  5. ECOG performance status 0-2
  6. Judged to be able to tolerate NST and Zevalin treatment based on institutional criteria.
  7. Signed written informed consent
  8. At least one fully HLA matched sibling without evident contraindications to the donation procedures and willing to sign consent for donation

Exclusion Criteria:

Patients must not have/be

  1. Abnormal renal function (creatinine > 1.5 x upper limit of normal (ULN)
  2. Abnormal hepatic function (bilirubin > 2 x ULN, ALT/AST>2x ULN)
  3. Cardiac ejection fraction <40% and/or other significant cardiac compromise
  4. Severe defects in pulmonary function tests or receiving continuous oxygen
  5. Severe concurrent illness, such as symptomatic congestive heart failure, severe arrhythmias, uncontrolled hypertension, diabetes, severe neurologic or psychiatric disorder or known HIV positive
  6. Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated except cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis & T1) that may impact on patients life expectancy or any cancer curatively treated < 3 years prior to study entry.
  7. History of prior allogeneic bone marrow transplant
  8. Evidence of active hepatitis B or C infection or positivity for hepatitis-B surface antigen
  9. Known type 1 hypersensitivity or anaphylactic proteins to any component of the Zevalin therapy or a history or presence of human anti-mouse antibodies (HAMA)
  10. A female patient who is pregnant or breast feeding and an adult of reproductive potential who is not employing an effective method of birth control during the study.
  11. CNS lymphoma
  12. Ongoing confirmed or suspected significant infection
  13. Prior treatment with radioimmunotherapy
  14. Other condition preventing participation in standard NST
  15. No fully matched sibling donor
Both
18 Years to 65 Years
No
Contact: Thomas Kiss, MD 514-252-3404 thomas.kiss@umomtreal.ca
Canada
 
NCT00807196
ZEV0701
Yes
Carole Deschambault/executive director, Hopital Maisonneuve-Rosemont
Maisonneuve-Rosemont Hospital
Bayer
Principal Investigator: Thomas Kiss, MD Maisonneuve-Rosemont Hospital
Maisonneuve-Rosemont Hospital
December 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP